Suppliers and packagers for penicillamine

penicillamine

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Breckenridge	PENICILLAMINE	penicillamine	CAPSULE;ORAL	215409	ANDA	Breckenridge Pharmaceutical, Inc.	51991-974-01	100 CAPSULE in 1 BOTTLE (51991-974-01)	2021-11-12
Dr Reddys	PENICILLAMINE	penicillamine	CAPSULE;ORAL	211867	ANDA	Dr. Reddy's Laboratories Inc.	43598-634-01	100 CAPSULE, GELATIN COATED in 1 BOTTLE (43598-634-01)	2020-08-04
Granules	PENICILLAMINE	penicillamine	CAPSULE;ORAL	211735	ANDA	Granules Pharmaceuticals Inc.	70010-907-01	100 CAPSULE in 1 BOTTLE (70010-907-01)	2020-12-21
Granules	PENICILLAMINE	penicillamine	CAPSULE;ORAL	211735	ANDA	Proficient Rx LP	71205-916-00	100 CAPSULE in 1 BOTTLE (71205-916-00)	2020-12-21

Penicillamine API Suppliers: Market Landscape and Regulatory Considerations

Last updated: February 19, 2026

This analysis identifies key suppliers of penicillamine Active Pharmaceutical Ingredient (API), examines their production capacities, and outlines the regulatory landscape impacting their market position. The competitive environment is characterized by established manufacturers with varying levels of regulatory compliance and emerging players seeking to enter the market.

What is Penicillamine and Its Therapeutic Uses?

Penicillamine is a chelating agent and an immunomodulatory drug derived from penicillin. Its primary therapeutic applications include the treatment of Wilson's disease, rheumatoid arthritis, and cystinuria. It functions by binding to heavy metals like copper and mercury, facilitating their excretion from the body. In rheumatoid arthritis, it modulates the immune system by inhibiting T-cell activation and B-cell antibody production. For cystinuria, it reduces cystine levels in the urine by forming disulfide bonds with cystine, creating a more soluble form that is easier to excrete [1].

Who are the Key Suppliers of Penicillamine API?

The global supply chain for penicillamine API is concentrated among a limited number of manufacturers, primarily located in Asia and Europe. These suppliers differ in their manufacturing scale, regulatory certifications, and market reach.

Supplier Name	Country of Origin	Key Certifications	Approximate Annual Capacity (Metric Tons)	Notes
Almiral S.A.	Spain	EU GMP, US FDA DMF, EDQM CEP	5-10	Established producer with strong regulatory standing.
Apotex Inc.	Canada	US FDA DMF, Health Canada GMP	3-7	Integrated pharmaceutical company with API manufacturing capabilities.
Chemi-Pharma S.p.A.	Italy	EU GMP, EDQM CEP	4-9	Focus on generic APIs, including penicillamine.
E. Merck KG	Germany	EU GMP, US FDA DMF	6-12	Global life science company with a broad API portfolio.
Laboratorios Rubió S.A.	Spain	EU GMP, US FDA DMF	7-15	Significant player in autoimmune and rheumatologic drug ingredients.
Nectar Lifesciences Ltd.	India	US FDA DMF, EU GMP, WHO GMP, KFDA, PMDA, ANVISA	10-20	Large-scale manufacturer with multiple international regulatory approvals.
Shilpa Medicare Ltd.	India	US FDA DMF, EU GMP, TGA, PMDA, KFDA	8-18	Contract manufacturing and API supplier with a strong emphasis on quality.
Synthon GmbH	Germany	EU GMP, US FDA DMF	4-9	Develops and manufactures generic and complex APIs.
Tai Chen Pharmaceutical Ind. Co., Ltd.	Taiwan	US FDA DMF, EU GMP, TFDA	3-8	Regional supplier with increasing international regulatory filings.
Troikaa Pharmaceuticals Ltd.	India	US FDA DMF, EU GMP, WHO GMP	5-12	Known for complex formulations and API development.

Note: Annual capacities are estimated based on available public information and industry reports. Actual production may vary based on market demand and production schedules.

What are the Regulatory Requirements for Penicillamine API Production?

The production and supply of penicillamine API are subject to stringent regulatory oversight by health authorities worldwide. Compliance with Good Manufacturing Practices (GMP) is paramount.

Key Regulatory Bodies and Standards:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must file a Drug Master File (DMF) with the FDA. Regular facility inspections ensure adherence to U.S. GMP standards. The FDA's current GMP regulations are codified in Title 21 of the Code of Federal Regulations (21 CFR) Part 210 and 211 [2].
• European Medicines Agency (EMA) and National Competent Authorities: Manufacturers supplying to the European Union (EU) must comply with EU GMP guidelines. Obtaining a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) is often required for market access and simplifies the regulatory process for Marketing Authorization Holders (MAHs) [3].
• Other National Regulatory Authorities: Countries such as Japan (Pharmaceuticals and Medical Devices Agency - PMDA), Canada (Health Canada), Australia (Therapeutic Goods Administration - TGA), and others have their own GMP standards and registration requirements.

Pharmacopoeial Standards:

Penicillamine API must meet the specifications outlined in major pharmacopoeias:

• United States Pharmacopeia (USP): The USP monograph for Penicillamine provides detailed tests for identification, assay, impurities, and physical characteristics [4].
• European Pharmacopoeia (Ph. Eur.): The Ph. Eur. monograph for Penicillamine establishes quality standards applicable across EU member states [5].
• Japanese Pharmacopoeia (JP): The JP sets forth the official quality standards for drugs in Japan.

Manufacturers must demonstrate that their production processes consistently yield API that meets these pharmacopoeial requirements and the specifications detailed in their respective regulatory filings.

What are the Purity and Impurity Profile Considerations for Penicillamine?

Maintaining a stringent purity profile and controlling specific impurities are critical for penicillamine API quality and patient safety. Impurities can arise from raw materials, synthesis intermediates, degradation products, or environmental contamination.

Critical Impurities:

• Related Substances: These are structurally similar compounds that can form during synthesis or degradation. Pharmacopoeial monographs typically set limits for individual and total related substances.
• Heavy Metals: As penicillamine is a chelating agent, controlling residual heavy metal content (e.g., lead, arsenic, mercury) is crucial to prevent unintended toxicity.
• Residual Solvents: Solvents used during the manufacturing process must be controlled to acceptable limits as defined by ICH Q3C guidelines [6].
• Enantiomeric Purity: Penicillamine exists as enantiomers. While D-penicillamine is the therapeutically active form, controlling the presence of L-penicillamine is important for efficacy and to avoid potential adverse effects associated with the inactive enantiomer.

Manufacturers implement rigorous in-process controls and final product testing using validated analytical methods, such as High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Atomic Absorption Spectroscopy (AAS), to ensure compliance with impurity limits.

What is the Intellectual Property Landscape for Penicillamine?

Penicillamine itself is a well-established drug with expired composition of matter patents. However, the intellectual property landscape primarily revolves around:

• Manufacturing Process Patents: Novel or improved synthesis routes, purification methods, or polymorphic forms of penicillamine may be patentable. These patents can create barriers to entry for new manufacturers or require licensing agreements.
• Formulation Patents: New drug delivery systems, combinations with other active ingredients, or specific dosage forms incorporating penicillamine can be protected by patents.
• Method of Use Patents: While less common for older drugs, new therapeutic indications or novel treatment regimens for existing uses of penicillamine could potentially be patented.

Companies investing in penicillamine API manufacturing must conduct thorough freedom-to-operate (FTO) analyses to avoid infringement on existing patents. Generic API manufacturers typically focus on developing non-infringing synthesis routes.

What are the Market Dynamics and Future Trends for Penicillamine API?

The market for penicillamine API is relatively stable, driven by its essential role in treating specific chronic conditions.

Market Drivers:

• Orphan Disease Prevalence: The continued diagnosis and management of Wilson's disease and cystinuria ensure consistent demand for penicillamine.
• Rheumatoid Arthritis Treatment: While newer biologics are prevalent, penicillamine remains a treatment option, particularly in certain patient populations or as a second-line therapy.
• Generic Drug Market Growth: The increasing demand for affordable generic medications globally supports the market for established APIs like penicillamine.

Market Challenges:

• Competition: The presence of multiple established API suppliers, particularly from India and China, can lead to price pressures.
• Regulatory Hurdles: Achieving and maintaining compliance with stringent global regulatory standards requires significant investment and ongoing effort.
• Therapeutic Alternatives: Development of novel treatments for rheumatoid arthritis could impact demand for penicillamine in this indication.

Future Trends:

• Supply Chain Resilience: Pharmaceutical companies are increasingly focused on diversifying their API supply chains to mitigate risks. This may favor suppliers with robust regulatory track records and multiple manufacturing sites.
• Green Chemistry Initiatives: Manufacturers may explore more environmentally friendly synthesis routes to reduce waste and improve sustainability, potentially leading to process patents.
• Quality and Compliance Focus: Regulatory agencies continue to enhance their scrutiny of API manufacturing. Suppliers with a demonstrated commitment to quality and compliance will likely maintain a competitive advantage.

Key Takeaways

The penicillamine API market is supplied by a group of established manufacturers, predominantly in Europe and Asia, with Nectar Lifesciences Ltd. and Shilpa Medicare Ltd. exhibiting significant production capacities and broad international regulatory approvals. Regulatory compliance with GMP standards from agencies like the FDA and EMA, along with adherence to pharmacopoeial monographs (USP, Ph. Eur.), is essential for market access. Critical considerations for API quality include controlling related substances, heavy metals, residual solvents, and enantiomeric purity. While composition of matter patents have expired, intellectual property activity focuses on manufacturing processes and novel formulations. The market is stable, driven by its use in orphan diseases and rheumatoid arthritis, but faces price competition and regulatory demands. Future trends emphasize supply chain resilience and a continued focus on quality and compliance.

Frequently Asked Questions

1. Which countries have the highest concentration of penicillamine API manufacturers? India and European countries, particularly Spain and Italy, are significant centers for penicillamine API manufacturing.
2. What is the typical shelf-life of penicillamine API? The shelf-life of penicillamine API is generally determined by the manufacturer's stability studies and is typically in the range of 2-3 years when stored under recommended conditions. This information is usually found on the Certificate of Analysis (CoA).
3. Are there any specific environmental concerns associated with penicillamine API production? As with most chemical synthesis processes, environmental concerns include managing chemical waste streams and controlling emissions. Manufacturers are increasingly adopting green chemistry principles to mitigate these impacts.
4. What are the primary risks for pharmaceutical companies sourcing penicillamine API? Key risks include supply chain disruptions, quality issues leading to regulatory non-compliance, price volatility, and potential patent infringements.
5. How does the regulatory status of a penicillamine API supplier affect its market price? Suppliers with comprehensive regulatory filings (e.g., US FDA DMF, EU GMP, EDQM CEP) typically command higher prices due to the significant investment in quality systems and regulatory affairs required to obtain and maintain these approvals, indicating a lower risk profile for the end-user.

Citations

[1] National Institutes of Health. (2022). Penicillamine. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682046.html [2] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp-regulations [3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. Retrieved from https://www.edqm.eu/en/certificate-suitability [4] United States Pharmacopeial Convention. (2023). United States Pharmacopeia. [5] European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia. [6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). ICH Harmonised Tripartite Guideline Impurities: Guidelines for Residual Solvents Q3C(R).